Aerie Pharmaceuticals clinical trials

Acquired by Alcon, Nov 21, 2022 · source ↗

The registry lists 36 studies whose lead sponsor is Aerie Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 13, 2025.

Studies

Recruiting first, then most recently updated. Showing 36 of 36. All Alcon studies →

• A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512CompletedNCT05493111Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)CompletedNCT05360966Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study Evaluating the Safety and Efficacy of AR-15512CompletedNCT05285644Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye DiseaseCompletedNCT04498182Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Rocklatan® EvaluationCompletedNCT05283395Phase 4

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy VolunteersCompletedNCT01997879Phase 1

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 MonthsCompletedNCT01699464Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04620135Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• A Study Assessing AR-13503 Implant in Subjects With nAMD or DMECompletedNCT03835884Phase 1

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal DystrophyCompletedNCT04498169Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study Evaluating Techniques for Measuring Tear ProductionCompletedNCT05497479Phase 1

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)CompletedNCT03739593Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular HypertensionCompletedNCT03284853Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanCompletedNCT03844945Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world SettingCompletedNCT03808688Phase 4

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular HypertensionCompletedNCT03310580Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT03233308Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02558400Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular PressureCompletedNCT02057575Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT02674854Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study of AR-13324 in Patients With Elevated Intraocular PressureCompletedNCT01528787Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic SolutionCompletedNCT02874846Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular PressureCompletedNCT01731002Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02207491Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionCompletedNCT02558374Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02246764Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionCompletedNCT02207621Phase 3

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureCompletedNCT01474135Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult VolunteersCompletedNCT02406287Phase 1

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• AR-12286 in Combination With LatanoprostCompletedNCT01302249Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Ocular Hypotensive Efficacy of AR-102CompletedNCT00523250Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular PressureCompletedNCT01060579Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)CompletedNCT00902200Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• 24-hour Efficacy of AR-12286CompletedNCT01330979Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysCompletedNCT01789736Phase 2

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon

• Formulation Comparison in Normal VolunteersCompletedNCT01250197Phase 1

  Sponsor listed in the registry: Aerie Pharmaceuticals · First submitted before Aerie Pharmaceuticals became part of Alcon